TVGN-489 is under clinical development by Tevogen Bio and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TVGN-489’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TVGN-489 overview
TVGN-489 is under development for the treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome causing coronavirus 2 (SARS-CoV-2) and long COVID. The therapy comprises of allogeneic (off-the-shelf) T-cells. It is being developed based on antigen-specific T cell technology. It is administered through intravenous route. It is being developed based on ExacTcell platform.
Tevogen Bio overview
Tevogen Bio, a subsidiary of Tevogen Bio Holdings Inc, is a biopharmaceutical company that develops and commercializes personalized immunotherapies. The company specializes in drug development utilizing the ExacTcell platform for therapeutic areas such as virology, oncology and neurology. Its pipeline products include TVGN 489 for SARS-CoV-2 infection in patients with B cell hematologic cancer, other cancers, rheumatoid arthritis and psoriatic arthritis; TVGN 920 for cervical cancer; TVGN 930 treats EBV-associated lymphomas TVGN 960 for mouth and throat cancer; and TVGN 601 targets multiple sclerosis. Tevogen Bio is headquartered in Warren, New Jersey, the US.
For a complete picture of TVGN-489’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.